li001

Study Shows Endoscopic Ultrasound Helps Guide Treatment in Early Gastric Cancer

Technology Innovation /

Accurate T staging in early gastric cancer (EGC) is critical because it determines treatment. Tumors limited to the mucosa (T1a) can often be treated with minimally invasive endoscopic procedures, while deeper tumors (T1b) usually require major surgery. A new study found that EUS had an overall accuracy of about 75%. It was very good at […]

Study Shows Endoscopic Ultrasound Helps Guide Treatment in Early Gastric Cancer Read More »

Hybrid Thermal Liquid Biopsy Model Improves Accuracy of Colorectal Cancer Detection

Diagnostics /

Colorectal cancer (CRC) is a major cause of death worldwide, and early-onset cases in people under 50 have risen sharply in Western countries. Although early detection can often cure the disease, common blood markers like CEA are not specific enough for reliable screening. In a recent study, researchers tested a new approach called Thermal Liquid

Hybrid Thermal Liquid Biopsy Model Improves Accuracy of Colorectal Cancer Detection Read More »

Blood-Based Biomarkers Show Promise for Early Detection of Colorectal Adenomas

Diagnostics /

Researchers are shifting toward blood-based biomarker tests to detect colorectal adenomas (CRAs), which are precancerous lesions that can lead to colorectal cancer. While colonoscopy and stool tests (FIT) are standard, blood tests are more convenient and may better detect non-bleeding lesions, improving patient compliance. Key approaches include noncoding RNAs (such as microRNAs and circular RNAs),

Blood-Based Biomarkers Show Promise for Early Detection of Colorectal Adenomas Read More »

5-Year CheckMate 274 Results Show Long-Term Benefit of Adjuvant Nivolumab in High-Risk Bladder Cancer

Treatment /

The 5-year results of the CheckMate 274 trial show that adjuvant nivolumab (Opdivo) provides lasting benefits for patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery. With nearly five years of follow-up, nivolumab significantly improved outcomes compared with placebo. The median disease-free survival was 21.9 months with nivolumab, compared with 11.0 months with placebo—almost double.

5-Year CheckMate 274 Results Show Long-Term Benefit of Adjuvant Nivolumab in High-Risk Bladder Cancer Read More »

Early Chromosome 1q Changes Linked to Pancreatic Cancer Risk

Research Advances /

Researchers discovered that extra copies of chromosome 1q drive early-stage pancreatic cancer. Unlike small mutations, these large chromosomal changes appear in nearly 40% of tumors and often show up in precancerous lesions before other mutations occur. The researchers identified two key genes, NCSTN and PSEN2, on chromosome 1q that regulate cell behavior. Using whole-genome sequencing and

Early Chromosome 1q Changes Linked to Pancreatic Cancer Risk Read More »

AI Model Improves Tumor Detection and Recurrence Prediction in Cervical Cancer

Technology Innovation /

A new study demonstrates an artificial intelligence (AI) system designed to improve the treatment of cervical cancer by automatically outlining tumors on MRI scans and predicting the risk of local recurrence within five years. Accurate tumor outlining is essential for planning radiotherapy. Researchers developed a 3D deep-learning model called MedNext-7L to perform this task. The model

AI Model Improves Tumor Detection and Recurrence Prediction in Cervical Cancer Read More »

FDA Grants Breakthrough Designation to Subcutaneous Amivantamab for HPV-Unrelated Head and Neck Cancer

Drug Approvals /

The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to amivantamab plus hyaluronidase-lpuj (Rybrevant Faspro), a subcutaneous treatment for adults with recurrent or metastatic, HPV-unrelated head and neck squamous cell carcinoma (HNSCC) whose disease has worsened after platinum-based chemotherapy and immunotherapy. This designation is based on results from the Phase 1b/2 OrigAMI-4 study.

FDA Grants Breakthrough Designation to Subcutaneous Amivantamab for HPV-Unrelated Head and Neck Cancer Read More »

Luspatercept Improves Transfusion Independence in Lower-Risk MDS

Drug Approvals /

A new study shows that luspatercept-aamt (Reblozyl) is effective and safe for treating anemia in transfusion-dependent, lower-risk Myelodysplastic Syndromes (MDS). About 50% of patients achieved at least eight weeks without needing red blood cell transfusions. Certain groups benefited more. Patients who were ring sideroblast (RS)–positive had higher response rates than RS-negative patients, and those with

Luspatercept Improves Transfusion Independence in Lower-Risk MDS Read More »

FDA Approves First Fixed-Duration, All-Oral Acalabrutinib–Venetoclax Regimen for CLL and SLL

Drug Approvals /

The U.S. Food and Drug Administration has approved a new all-oral treatment combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This is the first fixed-duration treatment in the U.S. that combines a BTK inhibitor with venetoclax, meaning patients can complete therapy in a set

FDA Approves First Fixed-Duration, All-Oral Acalabrutinib–Venetoclax Regimen for CLL and SLL Read More »

Bispecific CAR T Therapy LV20.19 Shows Strong Responses but High Immune Toxicity in Relapsed CLL

Treatment /

New data from a phase 1/2 study presented at the Transplantation & Cellular Therapy Meetings show that the bispecific CAR T-cell therapy LV20.19 is highly effective for patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), but it also brings important safety concerns. In the study of 18 patients who had received a median of

Bispecific CAR T Therapy LV20.19 Shows Strong Responses but High Immune Toxicity in Relapsed CLL Read More »